米托蒽醌治疗侵袭性多发性硬化症诱发的急性髓系白血病。
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.
作者信息
Capobianco Marco, Malucchi Simona, Ulisciani Stefano, Fava Carmen, Cambrin Giovanna Rege, Avonto Luigina, Saglio Giuseppe, Bertolotto Antonio
机构信息
Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica, Aou S Luigi Gonzaga, Regione Gonzole 10, Orbassano TO, Italy.
出版信息
Neurol Sci. 2008 Jun;29(3):185-7. doi: 10.1007/s10072-008-0934-1. Epub 2008 Jul 9.
Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.
急性髓系白血病（治疗相关急性髓系白血病，t-AML）是米托蒽醌治疗最严重的不良事件之一，但多发性硬化症（MS）患者的确切风险尚不清楚。我们描述了一例患者在停用米托蒽醌11个月后发生t-AML的病例。该患者接受了多药化疗和自体骨髓移植，t-AML完全缓解，神经疾病病情稳定。
Zotero 插件